Action to Control Cardiovascular Risk in Diabetes (ACCORD) "ACCORD"
Active, not recruiting
Phase 3 Results N/ASummary of Purpose
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 4 December 2009.
| 1 Sep 1999 | 27 Oct 1999 | 1 Jun 2009 | 1 Jun 2010 | 1 Feb 2009 | Unavailable |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Basics
Interventions See All
- Hypoglycemic Agents, Intensive BP treatment. Fenofibrate + simvastatin, Standard glycemia control, Standard BP control,
- Hypoglycemic Agents
- Intensive BP treatment
Conditions See All
Sponsors See All
Trial Design
- Allocation: Randomized
- Masking: Open Label
- Purpose: Prevention
- Endpoint: Efficacy Study
- Intervention: Factorial Assignment
Contacts
Not available
View Trial Locations
Recruitment
- Enrollment: 10,251
- Gender: Both
- Minimum Age: 40 Years
- Accepts Healthy Volunteers: No
- 7 locations, 2 countries
Principal Investigator
- William Friedewald, MD
Columbia University Department of Biostatistics
- Denise Simons-Morton, MD, PhD
National Heart, Lung, and Blood Institute (NHLBI)
- Robert Byington, PhD
Wake Forest University, Winston-Salem, NC
